What is Naloxone?

Naloxone is a safe, highly effective chemical compound that reverses the effects of opiates such as heroin. It has been used in clinical settings as an emergency treatment for opiate overdose for 40 years. In the USA and Europe, Take Home Naloxone programs have been linked with reductions in drug deaths of up to 34% (1). Naloxone has been approved for use in Canada for over 40 years and is on the World Health Organization List of Essential Medicines. Naloxone has no potential for abuse – in the absence of narcotics it exhibits essentially no pharmacologic activity. Naloxone will work only for drugs in the opiate/opioid family – it is not effective for overdoses of other drugs such as cocaine.

How can Naloxone help reduce the number of drugs deaths?

Naloxone can play a major role in preventing deaths – especially if it can be administered to someone in overdose as early as possible. To maximize the impact of Naloxone on drug deaths, it is necessary to have Naloxone available at the scene of the overdose before specialist help arrives. This means that Naloxone has to be available to members of the community for emergency use.

Access to Naloxone varies around the world, including take-home doses for people who use illicit drugs in Europe and Australia, and in Edmonton and Toronto. Scotland introduced a National Patient Group Directive in August 2010 to ease the development of take-home Naloxone programs. Patient Group Directives (PGD) allow Naloxone to be prescribed by appropriately qualified nurses and pharmacists. In Scotland, any person released from prison at risk of overdose is given training and a Naloxone kit (2). Naloxone is available over the counter in Turin, Italy. There are over 180 successful take-home Naloxone programs in the U.S., such as Project Lazarus in North Carolina, which has helped to distribute Naloxone to individuals who are at risk due to prescribed opiates (3).

In Canada, Naloxone is controlled as a Prescription Only Medicine (POM) under Schedule F of the Regulations for Canada’s Food and Drug Act. It is prescribed by doctors, on a named patient basis only, to those deemed to be at risk of opiate overdose. The availability of Naloxone is also affected by the provincial legislation governing pharmacies as well as professional bodies such as provincial colleges of physicians and surgeons.

[1] Scottish Drugs Forum. Take-home Naloxone: Reducing Drug Deaths. Available here.
[2] National Services Scotland. 2012. National Naloxone Programme Scotland Monitoring Report – Naloxone Kits Issued in 2011/12. Available here.
[3] Dasgupta, N. et al. 2008. “Project Lazarus: Overdose Prevention and Responsible Pain Management.” North Carolina Board of Medicine: Forum, p. 8.  Available here.
Connie Carter

About Connie Carter

Connie Carter, Ph.D. is the Senior Policy Analyst at the CDPC and a graduate of the UVIC Department of Sociology. She received a Bombardier Fellowship for her work analyzing citizen groups and government policy-makers as they responded to the issue of crystal meth use in BC in the early 2000s.

Sign up for latest news and updates

World AIDS Day 2016 – Three Papers To... December 1, 2016

World AIDS Day 2016 is on December 1st. View three important publications relating HIV/AIDS to harm reduction and drug policy. We will continue to work towards the equitable, safe and dignified treatment…

We’ve Been Here Before – Overdose Deaths in... November 24, 2016

Former BC Chief Coroner Vince Cain, in his report on British Colombia’s opioid overdose catastrophe in the nineties, conducted a thorough analysis of the problem we were facing then. Among…

The Canadian Drug Policy Coalition on Cannabis Regulation August 17, 2016

Canada is at a turning point in terms of cannabis policy. The Task Force on Marijuana Legalization and Regulation has released its discussion paper for input. The Task Force proposes five elements…

Survey sheds light on safety issues around drug... June 21, 2016

Originally posted on straight.com on June 9th, 2016 at 1:43 PM Stacey Forrester is a Vancouver-based harm-reduction advocate and nurse involved in projects on health and safety at live-music events and is focusing her…

Canada charts a new path on drug policy May 19, 2016

Scott Bernstein is the global drug policy program officer at the New York-based Open Society Foundations. He’s also the former health and drug policy campaigner for Pivot Legal Society, where he initiated…

Are 420 gatherings still relevant? April 22, 2016

On April 20th, or 420, I spoke with several reporters. They were particularly interested in my thoughts on 420 protests calling for the legalization of cannabis and whether such gatherings…